Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Checkmate Pharmaceuticals, Inc. | d18214dex321.htm |
| EX-31.2 - EX-31.2 - Checkmate Pharmaceuticals, Inc. | d18214dex312.htm |
| EX-31.1 - EX-31.1 - Checkmate Pharmaceuticals, Inc. | d18214dex311.htm |
| EX-21.1 - EX-21.1 - Checkmate Pharmaceuticals, Inc. | d18214dex211.htm |
| EX-10.13 - EX-10.13 - Checkmate Pharmaceuticals, Inc. | d18214dex1013.htm |
| EX-4.3 - EX-4.3 - Checkmate Pharmaceuticals, Inc. | d18214dex43.htm |
| 10-K - 10-K - Checkmate Pharmaceuticals, Inc. | d18214d10k.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Checkmate Pharmaceuticals, Inc.:
We consent to the incorporation by reference in the registration statement (No. 333-244375) on Form S-8 of Checkmate Pharmaceuticals, Inc. of our report dated March 29, 2021, with respect to the consolidated balance sheets of Checkmate Pharmaceuticals, Inc. and subsidiary as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes, which report appears in the December 31, 2020 annual report on Form 10-K of Checkmate Pharmaceuticals, Inc.
/s/ KPMG LLP
Boston, Massachusetts
March 29, 2021